BridgeBio Pharma, Inc. (BBIO) Stock Price & How to Invest

Last updated November 2026

Short answer

BBIO is BridgeBio Pharma, a commercial-stage biopharma whose value hinges on Attruby (acoramidis), a fast-growing heart drug for ATTR-CM, plus a genetic-disease pipeline. Investing in BBIO is a bet that Attruby keeps taking share from Pfizer and Alnylam and that new launches diversify the story before the loss-making phase ends. As of November 20, 2026 the shares closed near $77, about 1% lower year to date and up about 20% over one year, with an FDA decision on BBP-418 due by November 27, 2026.

BBIO stock price

As of 2026-11-20, BridgeBio Pharma, Inc. (BBIO) last closed at $76.03, up 11.6% over the past year. Over the past 52 weeks it has traded between $63.30 and $90.17.

BBIO last close
$76.03
1 day
-2.75%
1 month
+12.24%
1 year
+11.63%
52-week range
$63.30 to $90.17
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or BridgeBio Pharma, Inc.'s investor relations page. Walnut is informational, not investment advice.

BBIO key stats

At $76.03 on November 20, 2026, BridgeBio Pharma, Inc. (BBIO) has a market cap of $14.8B.

Market cap
$14.8B
Beta
0.94

Market cap, P/E and yield are measured at the $76.03 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with BridgeBio Pharma, Inc. (BBIO)?

The last two weeks for BridgeBio Pharma, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • BBIO closed at $76.03 on November 20, 2026, down 2.9% over the past five trading days (from $78.30).
  • On November 13, 2026, Morgan Stanley raised its target to $91.00 from $88.00 (Overweight).

BridgeBio Pharma, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

BridgeBio Pharma, Inc. (BBIO) latest quarter

BridgeBio reported revenue of $353 million for Q3 2026, up 193% from a year earlier (BridgeBio, Oct 29, 2026).

Revenue
$353 million
up 193% from a year earlier
Diluted EPS
-$0.42
n/a
Net product revenue
$253 million
up 134% from a year earlier

Source: BridgeBio Q3 2026 results, Oct 29, 2026. Full earnings breakdown

What does BridgeBio Pharma, Inc. (BBIO) do?

BridgeBio Pharma (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on genetic diseases and genetically driven cancers. Its commercial engine is Attruby (acoramidis), an oral TTR stabilizer approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and often underdiagnosed heart condition. Attruby competes in a market long dominated by Pfizer's tafamidis franchise, and BridgeBio has been rapidly building prescriber and patient uptake since launch.

The investment picture is a high-growth, still-unprofitable commercial biopharma. Revenue is scaling quickly: third-quarter 2026 revenue was about $353 million, up from about $244 million in the second quarter, and Yahoo Finance puts year-over-year growth in the latest quarter near 193%. Trailing twelve month revenue reached about $946 million. The company still reports large net losses (about $592 million over the trailing twelve months), but the third-quarter loss shrank to about $83 million, or about $0.42 per share, narrower than the roughly $0.56 analysts expected and the first quarter in the last four where the loss beat estimates. Beyond Attruby, BridgeBio is trying to diversify with three genetic-disease programs under FDA review: BBP-418 in limb-girdle muscular dystrophy (decision expected by November 27, 2026), infigratinib in achondroplasia (priority review, decision expected by February 4, 2027), and encaleret in ADH1 (decision expected by May 8, 2027). The stock trades at a premium valuation, about 16 times trailing sales, that prices in continued Attruby momentum and pipeline success, so results and FDA decisions matter a great deal.

The shares recovered some ground after the quarter. As of November 20, 2026 BBIO closed near $77.24, up about 13% over the past month, about 1% lower year to date and up roughly 20% over the past year, still below a 52-week high of about $93.42. November brought more supportive data: at the American Heart Association meeting BridgeBio presented a real-world study in which acoramidis was associated with a lower risk of worsening heart failure than tafamidis, along with ATTRibute-CM analyses showing fewer heart failure events within one month of starting treatment.

What's driving BridgeBio Pharma, Inc. (BBIO)?

1. Attruby (acoramidis) commercial ramp

Total company revenue rose to about $353 million in Q3 2026, from about $195 million in Q1 and $244 million in Q2, as Attruby prescriptions and prescriber counts expanded. BridgeBio points to near-complete TTR stabilization and a broad label as differentiators versus Pfizer's tafamidis. In October and November 2026 it presented independent real-world health record studies associating acoramidis with better clinical outcomes and a lower risk of worsening heart failure than tafamidis, plus new kidney-function and first-line treatment data at the International Symposium on Amyloidosis. Continued share gains in the large, underdiagnosed ATTR-CM market are the core driver of the story.

2. Pipeline diversification and 2026 filings

BridgeBio is pushing to become more than a one-drug company with three genetic-disease programs under FDA review. BBP-418 for LGMD2I/R9 has a decision expected by November 27, 2026, one week after the latest close. Infigratinib for achondroplasia was granted priority review in October 2026, with a decision expected by February 4, 2027. Encaleret for ADH1, which posted further Phase 3 CALIBRATE data in October, has a decision expected by May 8, 2027. Each approval would add a potential first-in-class launch.

3. Improving financial profile and balance sheet

Rising Attruby revenue plus royalty income has strengthened the business, and management authorized a $500 million share repurchase program in May 2026. Yahoo Finance data shows about $1.54 billion of cash against roughly $3.38 billion of debt as of September 2026, and trailing free cash flow of about -$287 million, so the balance sheet still depends on revenue growth. Analysts expect revenue of about $1.1 billion in 2026 and $1.66 billion in 2027, with the loss per share narrowing from about $2.45 to about $0.27. The third quarter's much smaller loss was the first concrete sign of operating leverage as revenue outgrows fixed commercial costs, a key part of the bull case.

4. Large under-penetrated ATTR-CM market

ATTR-CM remains widely underdiagnosed, so improved awareness and diagnosis can expand the treated population for all approved therapies. BridgeBio benefits from being one of only a handful of stabilizer options, alongside Pfizer and Alnylam. Growth in new diagnoses is a tailwind independent of head-to-head share shifts.

What are the risks to BridgeBio Pharma, Inc. (BBIO)?

The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. Pfizer's entrenched tafamidis franchise and Alnylam's vutrisiran (Amvuttra) are well-funded rivals fighting for the same patients. Any FDA delay, rejection, request for more data, or narrower-than-expected label for BBP-418 (decision due by November 27, 2026), infigratinib, or encaleret would push out the diversification timeline. The company is still unprofitable, with a trailing net loss near $592 million and roughly $3.38 billion of debt, and although the third-quarter loss beat estimates, the three quarters before it came in wider than expected. Pricing pressure, slower diagnosis growth, or a valuation that still embeds heavy optimism (about 16 times trailing sales) could all weigh on the shares.

What is the BridgeBio Pharma, Inc. (BBIO) forecast?

20 analysts publish price targets on BBIO, averaging $107.00 as of November 2026, or +40.7% against the $76.03 share price on November 20, 2026. The published targets run from $80.00 to $156.00, a wide spread, and the ratings split 19 buy, 3 hold, 0 sell. Over the last six months there have been 6 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BBIO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is BBIO a buy or a sell?

We give no verdict on BridgeBio Pharma, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Attruby (acoramidis) commercial ramp. Total company revenue rose to about $353 million in Q3 2026, from about $195 million in Q1 and $244 million in Q2, as Attruby prescriptions and prescriber counts expanded. The most optimistic published target, $156.00, assumes this works close to its best case.

The case against. The dominant risk is concentration: Attruby is BridgeBio's only approved commercial product, so near-term performance is highly dependent on a single therapy in a competitive market. The most pessimistic target, $80.00, is roughly what BBIO is worth if this bites instead.

Read the full bull and bear case on BBIO, including what would have to change to break either one. Walnut is not an investment adviser.

Has BridgeBio Pharma, Inc. (BBIO) split its stock?

No. BridgeBio Pharma, Inc. (BBIO) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is BridgeBio Pharma, Inc. (BBIO) valued?

Market cap, P/E and dividend yield at today's price are in the BBIO key stats above. The business figures below come from BridgeBio Pharma, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$946M
  • Revenue (Q3 2026): ~$353M, up ~193% year over year
  • Q3 2026 EPS vs estimate: ~-$0.42 vs ~-$0.56
  • Net income (TTM): ~-$592M
  • Gross margin: ~94%
  • Cash / debt (Sep 2026): ~$1.54B / ~$3.38B

As of November 2026: BBIO trades at about 16 times trailing revenue, a multiple that rests on continued Attruby growth and pipeline launches, since the company still loses money. Third-quarter revenue nearly tripled year over year and the loss per share beat estimates for the first time in four quarters, and the shares are roughly flat in 2026 after a 13% rise over the past month. The 20 analysts tracked by Yahoo Finance hold an average target near $107, above the November 20 close of about $77, with the BBP-418 FDA decision due by November 27.

Who competes with BridgeBio Pharma, Inc. (BBIO)?

ATTR-CM stabilizers and RNAi therapies

Pfizer's tafamidis franchise (Vyndaqel/Vyndamax) is the entrenched incumbent approved since 2019, and Alnylam's vutrisiran (Amvuttra) competes with an RNAi approach. These are the direct rivals to Attruby for the same heart-amyloidosis patients.

Rare and genetic-disease biopharma

BridgeBio competes for pipeline value and capital with other rare-disease developers such as Alnylam, Ionis, Ultragenyx, and BioMarin, which pursue genetically defined conditions and, in some cases, overlapping indications like achondroplasia and skeletal disorders.

Large-cap pharma with cardiovascular and rare-disease reach

Diversified players including Pfizer, AstraZeneca, and Novartis have the scale, sales infrastructure, and cash to expand in cardiovascular and rare-disease markets, representing broader competitive and partnership pressure on a smaller company like BridgeBio.

What stocks are similar to BridgeBio Pharma, Inc. (BBIO)?

Other names that sit close to BBIO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in BridgeBio Pharma, Inc. (BBIO)

There are three common ways to get BBIO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BBIO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BBIO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on BridgeBio Pharma, Inc. (BBIO)

BBIO is a single-product growth-biopharma story riding Attruby's rapid ramp, with pipeline launches and profitability still ahead of it. Third-quarter revenue of about $353 million beat the pace of earlier quarters and the loss narrowed, and three FDA decisions are scheduled between late November 2026 and May 2027.

More on BridgeBio Pharma, Inc. (BBIO)

Whether BBIO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BBIO a buy or a sell?, and where the stock could go from here in the BBIO stock forecast.

For income investors, whether BBIO pays a dividend and how the payout looks is covered in does BBIO pay a dividend? And to weigh BBIO against a peer, read the full side-by-side comparisons: BBIO vs CM and BBIO vs PFE.

Wondering how BBIO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about BridgeBio Pharma, Inc.

Ask Walnut's AI anything about BBIO and see how it fits what you own.

FAQ

What does BridgeBio Pharma (BBIO) do?

+

BridgeBio is a biopharmaceutical company that develops medicines for genetic diseases and genetically driven cancers. Its lead product, Attruby (acoramidis), treats transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition, and it has additional rare-disease programs in development.

What is Attruby and why does it matter to BBIO?

+

Attruby (acoramidis) is BridgeBio's FDA-approved oral TTR stabilizer for ATTR-CM, launched in December 2024. It is the company's only approved commercial product and the primary driver of revenue, so its uptake against Pfizer and Alnylam largely defines BBIO's near-term financial performance.

Is BridgeBio profitable?

+

No. Despite rapidly growing Attruby revenue, BridgeBio still reports net losses, with trailing net income around negative $592 million as of September 2026, as it spends heavily on commercialization and R&D. The third-quarter loss narrowed to about $83 million, and analysts expect the loss per share to shrink to about $0.27 in 2027. Reaching sustained profitability depends on continued revenue growth outpacing operating costs.

How fast is BBIO's revenue growing?

+

Very fast off a small base. Total revenue was about $195 million in Q1 2026, about $244 million in Q2 and about $353 million in Q3, when Yahoo Finance puts year-over-year growth near 193%. Trailing twelve-month revenue was about $946 million as of September 2026, and analysts expect roughly $1.1 billion for full-year 2026 and $1.66 billion for 2027.

Who are BridgeBio's main competitors?

+

In ATTR-CM, Attruby competes with Pfizer's tafamidis franchise (Vyndaqel/Vyndamax) and Alnylam's vutrisiran (Amvuttra). More broadly, BridgeBio competes with rare-disease developers such as Ionis, Ultragenyx, and BioMarin, and with large-cap pharma in cardiovascular and genetic-disease markets.

What are BBIO's key upcoming catalysts?

+

BridgeBio has three FDA decisions ahead: BBP-418 for LGMD2I/R9 by November 27, 2026; infigratinib for achondroplasia, which received priority review, by February 4, 2027; and encaleret for ADH1 by May 8, 2027. The company is also presenting new acoramidis data at investor and medical conferences in November and December. These filings aim to diversify beyond Attruby.

What are the biggest risks for BBIO?

+

The main risk is product concentration, since Attruby is BridgeBio's only approved drug in a competitive market against Pfizer and Alnylam. Other risks include FDA delays or rejections for pipeline candidates, continued cash burn and net losses, pricing pressure, and a premium valuation that assumes strong future growth.

How much cash does BridgeBio have?

+

Yahoo Finance data shows about $1.54 billion of cash as of September 2026, up from about $720 million in June, against roughly $3.38 billion of debt. BridgeBio authorized a $500 million share repurchase program in May 2026. Trailing free cash flow is still negative at about $287 million, so the balance sheet still leans on Attruby's growth.

How did BridgeBio do in its latest quarter?

+

In the third quarter of 2026, reported on October 29, BridgeBio posted revenue of about $353 million, up from about $244 million in the second quarter, and a net loss of about $83 million, or about $0.42 per share, narrower than the roughly $0.56 loss analysts expected. For the fourth quarter, consensus calls for revenue near $304 million and a loss of about $0.50 per share.

How has BBIO stock performed in 2026?

+

As of November 20, 2026 BBIO closed near $77.24, about 1% lower year to date and about 4% lower over three months, but up about 13% over the past month and about 20% over the past year. Its 52-week range is roughly $62.50 to $93.42. Walnut is not an investment adviser.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with BridgeBio Pharma, Inc.'s investor relations page or your broker before making investment decisions.